A. Zouhair, M. Ozsahin, M. Schaffer, S. Albrecht, F. Camus, P. Jichlinski, R.-O. Mirimanoff, A. Bischof Delaloye, J.-Y. Meuwly and J.O. Prior Pages 2492 - 2502 ( 11 )
Positron emission computed tomography (PET) is a functional, noninvasive method for imaging regional metabolic processes that is nowadays most often combined to morphological imaging with computed tomography (CT). Its use is based on the well-founded assumption that metabolic changes occur earlier in tumors than morphologic changes, adding another dimension to imaging. This article will review the established and investigational indications and radiopharmaceuticals for PET/CT imaging for prostate cancer, bladder cancer and testicular cancer, before presenting upcoming applications in radiation therapy.
Prostate cancer,bladder cancer,testicular cancer,positron emission tomography,F-18-fluorodeoxyglucose
, , , , , , , , , Department of Radiation Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Bugnon 46, CH-1011 Lausanne, Switzerland.